Kidney dysfunction after hematopoietic cell transplantation-Etiology, management, and perspectives

Jaguś, Dorota; Lis, Karol; Niemczyk, Longin; Basak, Grzegorz W.

doi:10.1016/j.hemonc.2018.07.004

Cited by 13 publications

(14 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In observational studies, CKD has shown a variable incidence in HSCT patients, varying between 18-66%, due to the different parameters used for CKD definition and the differences in the duration of follow-ups ( 69 – 71 ). In general, renal dysfunctions are multifactorial complications that can be caused by pre-transplant underlying diseases and comorbidities, conditioning regimens, transplant complications and prophylaxis treatments ( 72 ).…”

Section: Hsct-derived Endocrine Sequelae Pathophysiologymentioning

confidence: 99%

“…Pre-existing renal pathologies, such as glomerulonephritis, develop from hematological malignancies for which HSCT intervention is planned, therefore, the underlying hematological diseases already provoke renal lesions before HSCT, increasing in this way the risk of severe renal failure in the long term HSCT survival ( 78 ). Moreover, comorbidities such as diabetes, hypertension, and arteriosclerosis have been shown to further contribute to renal failure after transplant ( 72 ).…”

Section: Hsct-derived Endocrine Sequelae Pathophysiologymentioning

confidence: 99%

“…Pre-operative conditioning regimes may damage the kidneys. Several chemotherapeutics have been reported to induce renal failure, such as pre-renal azotemia and acute tubular necrosis, due to their nephrotoxicity, so a reduction of their dosage in HSCT recipients has been recommended ( 72 , 79 , 80 ).…”

Section: Hsct-derived Endocrine Sequelae Pathophysiologymentioning

confidence: 99%

See 2 more Smart Citations

Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism

et al. 2023

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is an established therapeutic strategy for the treatment of malignant (leukemia and lymphoma) and non-malignant (thalassemia, anemia, and immunodeficiency) hematopoietic diseases. Thanks to the improvement in patient care and the development of more tolerable conditioning treatments, which has extended the applicability of therapy to the elderly, a growing number of patients have successfully benefited from HSCT therapy and, more importantly, HSCT transplant-related mortality has consistently reduced in recent years. However, concomitantly to long term patient survival, a growing incidence of late HSCT-related sequelae has been reported, being variably associated with negative effects on quality of life of patients and having a non-negligible impact on healthcare systems. The most predominantly observed HSCT-caused complications are chronic alterations of the endocrine system and metabolism, which endanger post-operative quality of life and increase morbidity and mortality of transplanted patients. Here, we specifically review the current knowledge on HSCT-derived side-effects on the perturbation of mineral metabolism; in particular, the homeostasis of calcium, focusing on current reports regarding osteoporosis and recurrent renal dysfunctions that have been observed in a percentage of HSC-transplanted patients. Possible secondary implications of conditioning treatments for HSCT on the physiology of the parathyroid glands and calcium homeostasis, alone or in association with HSCT-caused renal and bone defects, are critically discussed as well.

show abstract

Section: Hsct-derived Endocrine Sequelae Pathophysiologymentioning

confidence: 99%

Section: Hsct-derived Endocrine Sequelae Pathophysiologymentioning

confidence: 99%

Section: Hsct-derived Endocrine Sequelae Pathophysiologymentioning

confidence: 99%

See 1 more Smart Citation

Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism

et al. 2023

View full text Add to dashboard Cite

show abstract

“…51 Chronic kidney disease (CKD) is an important late morbidity among survivors of allogeneic HCT and occurs at a higher incidence (14%) in this population as compared with autologous HCT recipients (4%). 52 In addition, although reduced intensity conditioning (RIC) regimens have a lower treatment-related mortality compared with myeloablative conditioning (MAC) regimens, the incidence of CKD is similar in allogeneic recipients receiving either RIC or MAC regimens. 53 CKD increases the risk of developing cardiovascular disease, infections, and other cancers; long-term outcomes also include the development of end-stage renal disease (ESRD).…”

Section: Renal Complicationsmentioning

confidence: 99%

Long‐term Follow‐up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics

et al. 2020

View full text Add to dashboard Cite

Annually, ~50,000 patients undergo hematopoietic stem cell transplantation (HCT) worldwide with almost 22,000 of these patients receiving HCT in the United States. HCT is a curative option for a wide range of hematologic malignancies, and advances in transplantation medicine have resulted in an increase in HCT survivors. It is anticipated that the number of HCT survivors will more than double from 242,000 in 2020 to ~500,000 in 2030. Survivors of HCT are at an increased risk of developing late complications due to exposure to chemotherapy and/or radiation in the pre‐, peri‐, and post‐HCT phases and these cumulative exposures have the potential to damage normal tissue. This tissue damage leads to the early onset of chronic health conditions resulting in premature mortality in HCT survivors, who have a 15‐year cumulative incidence of severe or life‐threatening chronic health conditions exceeding 40%. Due to the significant burden of morbidity in HCT survivors and the delay in the development of long‐term complications, this delicate patient population requires life‐long monitoring due to the risk for neuropsychological, cardiac, pulmonary, renal, hepatic, ocular, skeletal, cardiac, endocrine, fertility, and sexual health complications, as well as secondary neoplasms. This review will focus on recent advances in screening, monitoring, and therapeutics for late‐occurring or long‐term complications in HCT survivors.

show abstract

“…A DRC é uma possível complicação do TCTH e a consequência mais grave é uma doença renal em estágio terminal (DRET) 3 . A identificação dos fatores de risco, o diagnóstico precoce e o tratamento da DRC antes ou após o TCTH-alo são importantes para um transplante seguro 4 .…”

Section: Introductionunclassified

Desfechos renais a longo prazo em crianças após transplante alogênico de células-tronco hematopoiéticas avaliados com equações de taxa de filtração glomerular estimada, níveis de creatinina e níveis de cistatina C

Gadashova¹,

Tunçay²,

Özek³

et al. 2023

Braz. J. Nephrol.

View full text Add to dashboard Cite

Resumo Antecedentes e objetivo: Com o uso generalizado do transplante alogênico de células-tronco hematopoiéticas (TCTH-alo), as complicações a longo prazo tornaram-se evidentes. O objetivo deste estudo foi determinar a prevalência e os fatores de risco do desenvolvimento de doença renal crônica (DRC) a longo prazo em pacientes submetidos a TCTH-alo na infância, e também investigar a superioridade das fórmulas de TFGe. Métodos: O presente estudo avaliou a DRC em pacientes que foram submetidos ao TCTH-alo. Analisamos as 94 crianças que receberam TCTH-alo na Universidade Ege em İzmir entre Agosto e Novembro de 2019. Os pacientes foram avaliados aos 2 anos após o transplante. A DRC foi definida como uma taxa de filtração glomerular (TFG) <90 mL/min/1,73 m2 usando equações de TFGe baseadas em creatinina sérica (CrS), cistatina C (CisC), e CrS mais CisC. Resultados: Em nosso estudo, 9 pacientes (9,4%), de acordo com a equação de Schwartz (à beira do leito), 59 (76,6%), de acordo com a equação DRC-TFGe-CisC, e 20 (26%) pacientes, de acordo com a equação DRC-TFGe-CrS-CisC, foram classificados com DRC. Quando a TFG é avaliada pela CisC, verificamos que o desenvolvimento precoce de lesão renal aguda (LRA), a reativação do citomegalovírus (CMV) pós-transplante e ter >120 meses durante o transplante foram associados ao desenvolvimento de DRC. Conclusão: Pode haver atraso na detecção da DRC quando usamos fórmulas baseadas em CrS em casos de TCTH-alo, que é um grupo de pacientes onde o diagnóstico e tratamento precoces da DRC são muito importantes.

show abstract

Kidney dysfunction after hematopoietic cell transplantation-Etiology, management, and perspectives

Cited by 13 publications

References 80 publications

Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism

Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism

Long‐term Follow‐up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics

Desfechos renais a longo prazo em crianças após transplante alogênico de células-tronco hematopoiéticas avaliados com equações de taxa de filtração glomerular estimada, níveis de creatinina e níveis de cistatina C

Contact Info

Product

Resources

About